60 Degrees Pharmaceuticals (SXTP) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SXTP 60 Degrees Pharmaceuticals

Watchlist

1.090
+0.190+21.11%

Trading Nov 25 15:51 ET

2.03MMarket Cap-564P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
AccesswireNov 22 09:00 ET
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
Zacks Nov 14 14:35 ET
60 Degrees Pharmaceuticals 3Q Loss/Shr 93c >SXTP
Dow JonesNov 14 14:34 ET
Express News | 60 Degrees Q3 2024 GAAP EPS $(0.93) Misses $(0.70) Estimate, Sales $135.00K Miss $242.00K Estimate
BenzingaNov 14 14:32 ET
Express News | 60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
ReutersNov 14 14:31 ET
10-Q: Q3 2024 Earnings Report
SECNov 14 13:48 ET · Announcements

Comments

Jazz Dancer

Nov 20 16:27

$60 Degrees Pharmaceuticals (SXTP.US)$
Poorly managed and selfish company SXTP does NOT care that their stock keeps falling and shareholders suffer losses !!!!

Jazz Dancer

Nov 19 07:16

$60 Degrees Pharmaceuticals (SXTP.US)$
this is the most disgusting stock Ive ever seen and hold. this one and FFIE are prefect partners! no, this one cannot be a partner to FFIE, because FFIE has risen to from 10 to 30% a few times in the last 3 months. this one increased backward to -10% a few times!

Stock_Drift

Nov 14 14:32

$60 Degrees Pharmaceuticals (SXTP.US)$

Jazz Dancer

Nov 12 21:29

$60 Degrees Pharmaceuticals (SXTP.US)$
rubbish stock SXTP has never risen to 20% for so long time. many good stiocks like XBP & SGD hava risen to 100%+ a few times already within few weeks. why those stocks have gone up so high and often, why can't this do? simple answer: bad management of the company!

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

SXTP 60 Degrees Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target